| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00003246-199303000-00006 |
| P698 | PubMed publication ID | 8440099 |
| P50 | author | Jean-Louis Vincent | Q3167023 |
| P2093 | author name string | S J Harris | |
| R M Schein | |||
| E A Panacek | |||
| P Nightingale | |||
| S M Opal | |||
| J L Zimmerman | |||
| J F Dhainaut | |||
| C J Fisher | |||
| S Stephens | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 318-327 | |
| P577 | publication date | 1993-03-01 | |
| P1433 | published in | Critical Care Medicine | Q5186605 |
| P1476 | title | Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group | |
| P478 | volume | 21 |
| Q35121122 | Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis |
| Q73563322 | Acute respiratory distress syndrome |
| Q34053411 | Acute respiratory distress syndrome. Potential pharmacologic interventions |
| Q35732033 | Advances in sepsis therapy |
| Q41371176 | Advances in the therapy for sepsis in children |
| Q71819061 | An Anti-Interleukin 8 Monoclonal Antibody That Interferes with the Binding of Interleukin 8 to Cellular Receptors and the Activation of Human Blood Neutrophils |
| Q85716911 | Animal models of sepsis |
| Q34450313 | Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases |
| Q54084914 | Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI. |
| Q33894893 | Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. |
| Q34866465 | Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis |
| Q41050793 | Applications of molecular biology and biotechnology: antibody therapy of sepsis |
| Q58135451 | Attenuating tumor necrosis factor α does not ameliorate other cytokine and peroxidase products during sepsis |
| Q24798503 | Bench-to-bedside review: fulfilling promises of the Human Genome Project |
| Q36787173 | Bench-to-bedside review: sepsis, severe sepsis and septic shock - does the nature of the infecting organism matter? |
| Q40816001 | Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin |
| Q27478107 | Changes in immune parameters and their correction in human cases of tick-borne encephalitis |
| Q35600970 | Chronic sepsis mortality characterized by an individualized inflammatory response |
| Q78078773 | Complexity of inflammatory mediators in acute respiratory distress syndrome (ARDS) |
| Q37409738 | Cytokine profile in elderly patients with sepsis |
| Q35746498 | Cytokine profile in severe Gram-positive and Gram-negative abdominal sepsis. |
| Q40409319 | Cytokine-processing enzymes. Stopping the cuts |
| Q36735729 | Cytokines and the immune response |
| Q78224965 | Cytokines contribute to early hepatic parenchymal injury and microvascular dysfunction after bilateral hindlimb ischemia |
| Q36990515 | Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view |
| Q74317164 | Deferoxamine reduces tissue injury and lethality in LPS-treated mice |
| Q45085268 | Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis |
| Q72220475 | Detection of cytoplasmic IL-1 beta in peripheral blood mononuclear cells from intensive care unit (ICU) patients |
| Q43990321 | Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis |
| Q90748175 | Differential Thermoregulatory and Inflammatory Patterns in the Circadian Response to LPS-Induced Septic Shock |
| Q81251191 | Discriminative power of inflammatory markers for prediction of tumor necrosis factor-alpha and interleukin-6 in ICU patients with systemic inflammatory response syndrome (SIRS) or sepsis at arbitrary time points |
| Q40960916 | Do monoclonal antibodies and anticytokines still have a future in infectious diseases? |
| Q41101333 | Early detection and markers of sepsis |
| Q34093709 | Endogenous Tetrapyrroles Influence Leukocyte Responses to Lipopolysaccharide in Human Blood: Pre-Clinical Evidence Demonstrating the Anti-Inflammatory Potential of Biliverdin. |
| Q73453315 | FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock |
| Q54605066 | Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit |
| Q40301326 | Febrile response induced by cecal ligation and puncture (CLP) in rats: involvement of prostaglandin E2 and cytokines |
| Q91899623 | Gene therapy in surgery: Part II: Application to septic shock and to organ transplantation |
| Q33919010 | Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia |
| Q33642547 | Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis. |
| Q34142714 | Have we overestimated the benefit of human(ized) antibodies? |
| Q50993827 | High tumor necrosis factor serum level is associated with increased survival in patients with abdominal septic shock: a prospective study in 59 patients. |
| Q36365024 | Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses |
| Q33811345 | Immune dysfunction in trauma |
| Q41101381 | Immunotherapy for sepsis |
| Q37235732 | Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis |
| Q35064976 | Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis |
| Q34655635 | Inhibiting TNF-α signaling does not attenuate induction of endotoxin tolerance |
| Q83861147 | Initial approach to the child who presents in presumed septic shock |
| Q35115377 | Interleukin 10 reduces mortality from severe peritonitis in mice |
| Q24198059 | Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock |
| Q40990069 | Is sepsis a mediator-inhibitor mismatch? |
| Q42124595 | Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta |
| Q41032480 | Mediator-specific therapies for the systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock: present and future approaches. |
| Q74689817 | Microvascular changes explain the "two-hit" theory of multiple organ failure |
| Q33538538 | Molecular basis of host-pathogen interaction in septic shock |
| Q34236658 | Monoclonal antibody therapy |
| Q41219022 | Monocyte deactivation--rationale for a new therapeutic strategy in sepsis |
| Q71776323 | Multivariable predictive models for adverse outcome of invasive meningococcal disease in children |
| Q40460313 | New Therapies for ARDS |
| Q40667577 | New perspectives on the management of septic shock in the cancer patient |
| Q40535998 | New strategies for combatting sepsis: the magic bullets missed the mark ... but the search continues |
| Q41429380 | Novel approaches to the prevention and therapy of neonatal bacterial sepsis. |
| Q80210901 | Pathophysiology of sepsis |
| Q35761448 | Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both? |
| Q79291844 | Pharmacokinetics of E5564, a Lipopolysaccharide Antagonist, in Patients with Impaired Hepatic Function |
| Q77882870 | Production of pro-inflammatory cytokines in human monocytes: not a cascade but the dependence on protein kinase C pathway |
| Q71952429 | Prostacyclin counteracts the increase in capillary permeability induced by tumour necrosis factor-alpha |
| Q41610123 | Role of cytokines in sepsis. |
| Q72809735 | Role of dialysis modality in responses of blood monocytes and peritoneal macrophages to endotoxin stimulation |
| Q40540763 | Sepsis and septic shock. II. Treatment. |
| Q40392363 | Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal |
| Q37655890 | Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding |
| Q37028885 | Severe sepsis and Toll-like receptors |
| Q43511666 | Soluble Cytokine Receptors and Receptor Antagonists Are Sequentially Released after Trauma |
| Q77118243 | Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis |
| Q54495243 | Staphylococcal enterotoxin A-induced hepatotoxicity is predominantly mediated by Fas ligand (CD95L). |
| Q47605987 | Stress Response to Hepatectomy in Patients with a Healthy or a Diseased Liver |
| Q73206649 | Subchronic exposure of cardiomyocytes to low concentrations of tumor necrosis factor alpha attenuates the positive inotropic response not only to catecholamines but also to cardiac glycosides and high calcium concentrations |
| Q35128911 | Such stuff as dreams are made on: mediator-directed therapy in sepsis |
| Q37627465 | Supplementation of parenteral nutrition with fish oil attenuates acute lung injury in a rat model |
| Q41632994 | Taming TNF: strategies to restrain this proinflammatory cytokine |
| Q71987757 | The Acute Respiratory Distress Syndrome |
| Q45045407 | The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock |
| Q35124866 | The Problems and Challenges of Immunotherapy in Sepsis* |
| Q93047898 | The Specific Organism: Not Bacterial Gram Type: Drives the Inflammatory Response in Septic Shock |
| Q41057587 | The cytokine response to critical illness |
| Q40617534 | The evolution of modern trauma care |
| Q41164173 | The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock |
| Q72769320 | The inflammatory/immune response in critical illness: role of the systemic inflammatory response syndrome |
| Q71833375 | The interval between a septic stimulus and hypoxia/reoxygenation affects cytokine elaboration by murine peritoneal macrophages |
| Q42415387 | The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis |
| Q37684858 | The response of the host microcirculation to bacterial sepsis: does the pathogen matter? |
| Q54638238 | The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. |
| Q73002037 | The tyrosine kinase inhibitor tyrphostin AG 126 reduced the development of colitis in the rat |
| Q42047821 | The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation. |
| Q40388242 | The vascular endothelium in septic shock. |
| Q58748338 | Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis |
| Q35098770 | Translational systems approaches to the biology of inflammation and healing |
| Q33618096 | Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha |
| Q72034411 | Tumor necrosis factor as the proximal mediator of sepsis--Or this too will pass |
| Q37366045 | Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. |
| Q35860048 | Ultrashort Antimicrobial Peptides with Antiendotoxin Properties |
| Q41750836 | Urosepsis in the critical care unit |
| Q79285415 | Which therapeutic prospects in the septic syndrome? |
| Q91899631 | [Liposome mediated gene transfer - the future therapy for sepsis and intraabdominal infection?] |
Search more.